Analysis of integrated clinical trial protocols in early phases of medicinal product development
Open accessThe DOI matches its Crossref record; 8 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: While in the past, most clinical trial applications (CTAs) following non-integrated (standard) protocols were used to investigate one primary objective concerning a (new) drug, nowadays, the use of integrated protocols investigating multiple objectives within the same CTA becomes more and more popular. The aims of the present study were to investigate the usage and the impact of integrated protocols on regulatory activities and to find the motivation for their increasing use. METHODS: Two thousand nine hundred sixty-nine phase I and I/II CTAs submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) during the time period from August 1, 2004, until August 31, 2014, were analysed with regard to protocol and sponsor status, duration until initial authorisation and the number of substantial amendments and their respective approval times. Additionally, applicants who submitted integrated protocols to BfArM were interviewed with respect to their opinion on integrated protocols in an online survey. RESULTS: The percentage of integrated protocols has constantly increased by approximately 10% within the last 10 years from 17.9% in 2004 to 28.2% in 2014. It could be shown that authorisation procedures with single integrated protocols take significantly longer until initial authorisation (58 vs. 53 days) requires more substantial amendments (1.9 vs. 1.2 amendments per CTA) and the approval of the entirety of amendments takes longer to process as compared to standard protocols (22 vs. 14 days). Nevertheless, applicants prefer the use of integrated protocols due to higher time and cost economy for the entire phase I development process. CONCLUSION: Although clinical trials (CTs) following integrated protocols are partly more time-consuming and costly, still, time and/or money may be saved during drug development due to the fact that overall, fewer CTs are needed than with standard protocols. Hence, the main reason for the increasing use of integrated protocols is improved time and cost efficiencies when conducting CTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The guideline is a revision of an earlier version dated 2007 and extends the existing EU guidance to address FIH and early phase clinical trials (CTs) with integrated protocols [2].”
From Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products (2018) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482
Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323 · cited 1×
“So far, new and adaptive study designs have been used primarily in phase II and III clinical trials [27, 28, 30, 33].”
MethodThe future of drug development: advancing clinical trial design
Orloff, J., Douglas, F., Pinheiro, J., Levinson, S., Branson, M., Chaturvedi, P., Ette, E., Gallo, P., Hirsch, G., Mehta, C., et al. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3025 · Cited by 158 · cited 2×
“The efforts for preparation and filing of complex CT protocols just like their processing time during assessment by the competent federal higher authority actually last longer [5, 14, 27] as compared to standard protocols.”
BackgroundMethodBenefits, challenges and obstacles of adaptive clinical trial designs
Chow, S.-C., & Corey, R. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-79 · Cited by 88
Lorch, U., O’Kane, M., & Taubel, J. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-84 · Cited by 47
Combined integrated protocol/basket trial design for a first-in-human trial
Derhaschnig, U., Gilbert, J., Jaeger, U., Böhmig, G. A., Stingl, G., & Jilma, B. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0494-z · Cited by 44 · cited 1×
“Furthermore, the internal hypothesis that integrated protocols lead to increased subsequent regulatory activities [6, 21, 23] could be confirmed.”
BackgroundLang, T. A. (2011) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2011.11-0151 · Cited by 34 · cited 2×
“So far, new and adaptive study designs have been used primarily in phase II and III clinical trials [27, 28, 30, 33].”
BackgroundMethodInnovative approaches to clinical development and trial design.
Orloff, J. J., & Stanski, D. R. (2011) · PubMed · doi:10.4415/ann_11_01_03 · Cited by 13 · cited 1×
“So far, new and adaptive study designs have been used primarily in phase II and III clinical trials [27, 28, 30, 33].”
Method
Research works printed but not linked: 3
- Hasford J (2016) String protocols from phase I to approval? Original title: Kettenprotokolle von der phase I bis zur Zulassung? 24. BVMA-symposium, Munich 11/25/2016
- Taubel J (2014) Adaptive early phase clinical trials in the UK. AGAH Symposium Bonn 10/30/2014. http://www.agah.eu/uploads/tx_news/2014_OCT30_AGAH_Bonn_Ver_1_NOFILTER.pdf. Accessed 05 Jun 2017
- Preußer, Heiko (2014) Critical aspects of umbrella protocols and adaptive designs from the viewpoint of an approving authority. Original Title: Kritische Gesichtspunkte zu Umbrella Protokollen und Adaptiven Designs aus der Sicht der Genehmigungsbehörde. AGAH Symposium Bonn 10/30/2014. http://www.agah.eu/uploads/tx_news/AGAH_2014_10_30_Preusser.pdf. Accessed 05 Jun 2017
Cited by
European Journal of Clinical Pharmacology
(2013) · European Journal of Clinical Pharmacology · doi:10.1007/228.1432-1041 · Cited by 608
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Master protocols in clinical trials: a universal Swiss Army knife?
Sudhop, T., Brun, N. C., Riedel, C., Rosso, A., Broich, K., & Senderovitz, T. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30271-2 · Cited by 35
Self-citationPractical risk management in early phase clinical trials
Coates, S., Täubel, J., & Lorch, U. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-02607-8 · Cited by 24
The European clinical trials regulation (No 536/2014): changes and challenges
Scavone, C., di Mauro, G., Pietropaolo, M., Alfano, R., Berrino, L., Rossi, F., Tomino, C., & Capuano, A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1680282 · Cited by 22
“Lastly, other reasons may have contributed to the decline in the number of CTAs among EU countries, including the lack of adequate infrastructures and of sufficient research training, the increase of the so-called integrated protocols, in which two or more primary objectives are analyzed at the same time (such as thos…”
Background
Metadata
- Authors
- Fruhner, K., Hartmann, G., & Sudhop, T.
- Affiliations
- University of Bonn (DE)
- Federal Institute for Drugs and Medical Devices (DE)
- Corresponding author
- Sudhop, Thomas
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2017-09-18
- Volume
- 73
- Issue
- 12
- Pages
- 1565-1577
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- PMC
- PMC5684304
- OpenAlex
- W2754958515
- Cited by
- 18
- References
- 9
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 4
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Journal of Clinical Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- clinical trial applications, drug approval, regulatory approval time, cost and time efficiency
- MeSH terms
- Clinical Protocols, Humans, Drug Design, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.